MARKSANS329.00

Marksans Pharma Ltd.

· Pharma & Health
₹ CrorePeersGRANULESMETROPOLISPARKHOSPSJLHLHCGRUBICONSHILPAMEDSPARCMcap ₹14,909 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation74.38.398.6
+ Finance Costs11.21.224.1
+ Interest Income-33.8-3.0-27.7
+ Fair Value (Gains) / Losses-4.30.42.9
+ Unrealised FX (Gain) / Loss3.0-0.5-22.4
+ Other Non-cash Items5.20.625.2
+ Other — Cash Effects are Investing / Financing-0.1-0.1-1.2
Changes in Working Capital
+ Inventories-112.7-19.5-38.7
+ Trade Receivables — Current-37.2-7.8-31.4
+ Other Financial Assets — Current-0.3-0.0-0.1
+ Other Financial Assets — Non-current0.8-0.1-0.2
+ Other Current Assets-22.3-1.6-0.8
+ Other Non-current Assets-7.3-0.00.1
+ Trade Payables — Current31.43.29.4
+ Other Financial Liabilities — Current3.30.41.1
+ Other Current Liabilities16.11.3-1.9
+ Provisions — Current0.9-0.10.1
+ Provisions — Non-current1.10.1-0.0
Cash from Operating Activities
Profit Before Tax (per I/S)423.550.4560.6690.5
+ Total Adjustments (incl. Working Capital)-70.8-17.137.2
Cash from Operations (pre-tax)352.833.3597.8
+ Income Taxes Paid122.312.6139.7
Cash from Operating Activities230.420.7458.1
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)208.817.3130.5
+ Disp of Fixed Assets0.90.11.0
+ Interest Received — Investing30.93.426.2
+ Other Inflows / (Outflows) — Investing36.38.9-145.0
Cash from Investing Activities-140.8-4.9-248.3
Cash from Financing Activities
+ Repayment of Borrowings12.50.6-6.5
+ Payment of Lease Liabilities28.40.038.4
+ Interest Paid5.22.72.8
+ Dividends Paid22.73.036.3
+ Income Taxes (Paid) / Refund — Financing0.00.20.0
Cash from Financing Activities-68.7-6.5-70.9
Net Changes in Cash (pre-FX)20.89.3138.9
+ Effect of FX Rate Changes on Cash0.00.0-0.6
Net Changes in Cash20.89.3138.4
Closing Cash403.3495.8634.1
Reference Items
EBITDA458.652.9600.8713.7
EBITDA Margin %21.0620.1620.3622.50
Free Cash Flow (CFO − Capex)21.63.4327.6327.6
Free Cash Flow to Equity-26.1352.1
Free Cash Flow per Basic Share0.480.077.237.23
Price to Free Cash Flow45.51
Cash Flow to Net Income0.730.541.09
Cash Paid for Taxes122.312.6139.7
Cash Paid for Interest5.22.72.8
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.